Study to Evaluate Safety and Efficacy of LifeLiver in Acute or Acute-on-Chronic Liver Failure Patients

Patient should have acute or acute‐on‐chronic liver failure and be registered in KONOS (Korean Network for Organ Sharing) system as a candidate of liver transplantation. Patients who meet the eligibility criteria will be assigned to control group or experimental group. Experimental group patients will receive LifeLiver treatment in addition to the best supportive care for the disease. Primary Objective: 1. To evaluate the efficacy of LifeLiver in terms of a comparison of 30 day‐survival rate between control group and experimental group. (after patient's KONOS (Korean Network for Organ Sharing) registration date) Secondary Objective: 1. To compare a median value of 2 week‐survival rate and duration of survival between both study groups 2. Survival analysis respect to each group of patients divided according to the KONOS status 3. To investigate safety and change of overall efficacy indicators in terms of Glasgow Coma Scale, West Heaven Criteria for hepatic encephalopathy, MELD (Model for End‐stage Liver Disease) score, blood ammonia, inflammatory cytokine